2. Metabolic Enzyme/Protease
  3. Mitochondrial Metabolism
  4. MASM7

MASM7 is a mitofusin activator, and can achieve mitochondrial fusion via mitofusins. MASM7 can increase Mito AR with an EC50 value of 75 nM in MEFs in concentration-responsively, and can promote mitochondrial fusion by directly activating MFN2 or MFN. MASM7 also demonstrates direct binding to the HR2 domain of MFN2 with Kd value of 1.1 μM.

For research use only. We do not sell to patients.

CAS No. : 920868-45-7

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
250 mg In-stock
500 mg In-stock
1 g In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

MASM7 Related Antibodies

Top Publications Citing Use of Products

    MASM7 purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2025 Jul 4:e70085.  [Abstract]

    The MFN2 agonist MASM7 (2 μM) significantly impeded the proliferative processes of BPH-1 cells elicited by LPS, manifested as reduced proportions of EdU‐positive proliferative cells.

    MASM7 purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2025 Jul 4:e70085.  [Abstract]

    The MFN2 agonist MASM7 (2 μM) reversed the LPS-triggered EMT switch in BPH-1 cells, characterised by the restoration of E-cadherin and the loss of vimentin.

    MASM7 purchased from MedChemExpress. Usage Cited in: CNS Neurosci Ther. 2025 Jul;31(7):e70508.  [Abstract]

    MASM7 (10 μg/10 μL; i.t.; once daily for 7 d) reduced the mRNA expression of IL‐1β and IL‐18 in skin/muscle incision and retraction (SMIR) rats compared with vehicle.

    MASM7 purchased from MedChemExpress. Usage Cited in: CNS Neurosci Ther. 2025 Jul;31(7):e70508.  [Abstract]

    MASM7 (10 μg/10 μL; i.t.; once daily for 7 d) decreased the expression of NLRP3, caspase-1, P20, P10, GSDMD, and GSDMD-N in skin/muscle incision and retraction (SMIR) rats.

    MASM7 purchased from MedChemExpress. Usage Cited in: CNS Neurosci Ther. 2025 Jul;31(7):e70508.  [Abstract]

    MASM7 (10 μg/10 μL; i.t.; once daily for 7 d) treatment alleviated the mitochondrial morphological injury in spinal neurons of skin/muscle incision and retraction (SMIR) rats. The labeled red boxes highlighted the mitochondrial ultrastructure. The red arrow represented the mitochondria.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    MASM7 is a mitofusin activator, and can achieve mitochondrial fusion via mitofusins. MASM7 can increase Mito AR with an EC50 value of 75 nM in MEFs in concentration-responsively, and can promote mitochondrial fusion by directly activating MFN2 or MFN. MASM7 also demonstrates direct binding to the HR2 domain of MFN2 with Kd value of 1.1 μM[1].

    In Vitro

    MASM7 (1-10 μM, 2 h) increases Mito AR with an EC50 value of 75 nM in MEFs in concentration-responsively, and can promote mitochondrial fusion by directly activating MFN2 or MFN[1].
    MASM7 (1-1000 μM, 5 min) demonstrates direct binding to the HR2 domain of MFN2 with Kd value of 1.1 μM[1].
    MASM7 (1 μM, 6 h) does not induce DNA damage in any of the cell lines[1].
    MASM7 (0-1.5 μM, 72 h) does not decrease cellular viability over the course of 72 h[1].
    MASM7 (1 μΜ, 6 h) does not induce caspase-3/7 activation in U2OS cells[1].
    MASM7 (0-1 μM, 6 h) increases mitochondrial membrane potential in WT MEFs[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    MASM7 Related Antibodies
    Molecular Weight

    453.58

    Formula

    C22H23N5O2S2
    CAS No.
    Appearance

    Solid

    Color

    White to yellow

    SMILES

    O=C(N)C1=C(SC2=C1CCC2)NC(C(C)SC3=NN=C(C4CC4)N3C5=CC=CC=C5)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (220.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.2047 mL 11.0234 mL 22.0468 mL
    5 mM 0.4409 mL 2.2047 mL 4.4094 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (5.51 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.08 mg/mL (4.59 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.85%

    SDS (393 KB)

    COA (254 KB) HNMR (202 KB) RP-HPLC (262 KB) LCMS (145 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.2047 mL 11.0234 mL 22.0468 mL 55.1171 mL
    5 mM 0.4409 mL 2.2047 mL 4.4094 mL 11.0234 mL
    10 mM 0.2205 mL 1.1023 mL 2.2047 mL 5.5117 mL
    15 mM 0.1470 mL 0.7349 mL 1.4698 mL 3.6745 mL
    20 mM 0.1102 mL 0.5512 mL 1.1023 mL 2.7559 mL
    25 mM 0.0882 mL 0.4409 mL 0.8819 mL 2.2047 mL
    30 mM 0.0735 mL 0.3674 mL 0.7349 mL 1.8372 mL
    40 mM 0.0551 mL 0.2756 mL 0.5512 mL 1.3779 mL
    50 mM 0.0441 mL 0.2205 mL 0.4409 mL 1.1023 mL
    60 mM 0.0367 mL 0.1837 mL 0.3674 mL 0.9186 mL
    80 mM 0.0276 mL 0.1378 mL 0.2756 mL 0.6890 mL
    100 mM 0.0220 mL 0.1102 mL 0.2205 mL 0.5512 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    MASM7 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    MASM7920868-45-7MASM 7MASM-7Mitochondrial Metabolismmitochondrialmitofusinsmolecule activatorMEFsInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    MASM7
    Cat. No.:
    HY-W187305
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.